Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 5/20 | 0.48 |
| ▸ | CTSK | P43235 | 3/20 | 0.47 |
| ▸ | CTSS | P25774 | 2/20 | 0.47 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | ITGB3 | P05106 | 11/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30089915 | 1.00 | CACNA1B (0.48) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL192185 | 0.99 | CACNA1B (0.48) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL376117 | 0.99 | CACNA1B (0.48) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL4233928 | 0.99 | CACNA1B (0.48) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL29050983 | 0.90 | CACNA1B (0.53) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL29050985 | 0.90 | CACNA1B (0.53) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL26895103 | 0.89 | CACNA1B (0.53) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL26296033 | 0.89 | CACNA1B (0.49) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL30445735 | 0.87 | CACNA1B (0.55) | CACNA1BCTSKCTSSHDAC4HDAC1 | |
| SCHEMBL14066376 | 0.86 | CACNA1B (0.44) | CACNA1BCTSKCTSSHDAC4HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040247639-A1 | Novel methods and compositions for the treatment or prevention of dysmenorrhoea and menstrual side effects: the use of phospholipase inhibitors | QUEENSLAND, THE UNIVERSITY OF (AU) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040247639-A1 | Novel methods and compositions for the treatment or prevention of dysmenorrhoea and menstrual side effects: the use of phospholipase inhibitors | PLA2G12A, PLA2G1B, PLA2G2E | CACNA1B 415/4885CTSK 663/4885CTSS 687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.